Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...

The USDA is considering vaccinating poultry against bird flu, potentially influencing exports while causing significant ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

The USDA considers vaccinating poultry for bird flu, while the EU supports Madrigal's liver drug Rezdiffra. Meanwhile, the ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...

The U.S. Food and Drug Administration (FDA) granted accelerated approval in March 2024 for Rezdiffra in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with ...

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U. CONSHOHOCKEN, Pa., June (GLOBE NEWSWIRE) -- Madrigal ...

The European Union's medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals' drug for ...